Treatment of 161 Men with Symptomatic Late Onset Hypogonadism with Long-Acting Parenteral Testosterone Undecanoate: Effects on Body Composition, Lipids, and Psychosexual Complaints

Elderly men may suffer from late-onset hypogonadism (LOH). The long-term effects of long-acting testosterone undecanoate (TU) in a large number of LOH men have not yet been reported. We analyzed the effects of normalization of plasma testosterone (T) in LOH men. The records of 161 men with LOH (base...

Full description

Saved in:
Bibliographic Details
Published in:Journal of sexual medicine 2010-11, Vol.7 (11), p.3765-3774
Main Authors: Permpongkosol, Sompol, Tantirangsee, Nakorn, Ratana-olarn, Krisada
Format: Article
Language:English
Subjects:
Adult
Age Factors
Aged
Aged, 80 and over
Analysis of Variance
Androgens - adverse effects
Androgens - blood
Androgens - therapeutic use
Body Composition - drug effects
Body Mass Index
Health Status Indicators
Humans
Hypogonadism - drug therapy
Hypogonadism - psychology
Infusions, Parenteral
International Index of Erectile Function
Late-Onset Hypogonadism
Lipids
Male
Middle Aged
Prostate Safety
Sex Hormone Binding Globulin
Sexual Dysfunction, Physiological - drug therapy
Sexual Dysfunction, Physiological - psychology
Statistics, Nonparametric
Surveys and Questionnaires
Testosterone - adverse effects
Testosterone - analogs & derivatives
Testosterone - blood
Testosterone - therapeutic use
Testosterone Deficiency Syndrome
Testosterone Undecanoate
Thai
Time Factors
Waist Circumference
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Elderly men may suffer from late-onset hypogonadism (LOH). The long-term effects of long-acting testosterone undecanoate (TU) in a large number of LOH men have not yet been reported. We analyzed the effects of normalization of plasma testosterone (T) in LOH men. The records of 161 men with LOH (baseline T12 months. The mean duration of treatment was 90.6 weeks (54 to 150 weeks). Body mass index (BMI), waist circumference, percentage body fat, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, prostate-specific antigen (PSA), and hematocrit were measured. Further the Aging Male Symptoms' scale (AMS) and the International Index of Erectile Function (IIEF-5 and 15) were scored. T therapy was associated with a significant decline in waist circumference (P=0.028) and percentage body fat (P
ISSN:1743-6095
1743-6109
DOI:10.1111/j.1743-6109.2010.01994.x